1. Home
  2. SAR vs MYGN Comparison

SAR vs MYGN Comparison

Compare SAR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$22.62

Market Cap

372.7M

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.79

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
MYGN
Founded
2007
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.7M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
SAR
MYGN
Price
$22.62
$4.79
Analyst Decision
Hold
Buy
Analyst Count
4
7
Target Price
$23.75
$7.64
AVG Volume (30 Days)
110.3K
1.0M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
14.43%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$6.86
Revenue Next Year
$0.39
$5.45
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
2.33
52 Week Low
$20.78
$3.76
52 Week High
$25.64
$8.59

Technical Indicators

Market Signals
Indicator
SAR
MYGN
Relative Strength Index (RSI) 50.59 48.86
Support Level $22.56 $4.25
Resistance Level $22.82 $5.52
Average True Range (ATR) 0.49 0.30
MACD 0.05 0.02
Stochastic Oscillator 48.24 45.24

Price Performance

Historical Comparison
SAR
MYGN

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: